Study of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus in AdultsResearch Question:
Does the vaccine mRNA-1345 prevent RSV illnesses?
Basic Study Information
Purpose:Study Reference #: STUDY00008423
RSV is a virus that causes respiratory tract infections, which affect the lungs. RSV
symptoms include runny nose, stuffy nose, wheezing, cough, sore throat, fever, and
shortness of breath. RSV is the most common cause of severe lung infections and hospitalizations
in young children and can cause lung infections in older adults. Both older adults
with other health conditions, such as heart or lung disease, and adults who have received
an organ transplant are at higher risk of serious illness from RSV infection. Vaccines
help protect people from disease by causing the body to produce antibodies, which
are proteins that fight off infection. There is currently no vaccine for RSV. This
clinical trial is studying a new vaccine called mRNA-1345 to see if it can prevent
RSV. You are eligible for this trial if you are 18–59 years old and have either diabetes,
coronary artery disease, congestive heart failure, or lung disease. You are also
eligible if you are >18 years old and have received an organ transplant more than
180 days ago.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Kari Steinmetz
Phone: (585) 273-2083
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search